L3VLUP
ProSign in

ENTA · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ENTAJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ENTA
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterENTAJNJ
Q3 20206 holders, $163m30 holders, $26.2bn
Q4 20206 holders, $144m32 holders, $26.6bn
Q1 20216 holders, $170m31 holders, $25.3bn
Q2 20215 holders, $143m37 holders, $25.6bn
Q3 20214 holders, $171m40 holders, $24.1bn
Q4 20214 holders, $183m33 holders, $25.2bn
Q1 20225 holders, $163m35 holders, $28.2bn
Q2 20223 holders, $74m33 holders, $26.9bn
Q3 20222 holders, $80m36 holders, $25.4bn
Q4 20222 holders, $72m35 holders, $27.6bn
Q1 20232 holders, $63m42 holders, $24.5bn
Q2 20232 holders, $41m38 holders, $25.0bn
Q3 20234 holders, $28m37 holders, $18.9bn
Q4 20233 holders, $28m31 holders, $19.0bn
Q1 20243 holders, $52m32 holders, $19.7bn
Q2 20243 holders, $39m35 holders, $20.4bn
Q3 20242 holders, $31m28 holders, $22.3bn
Q4 20241 holders, $12m37 holders, $20.4bn
Q1 20252 holders, $12m32 holders, $20.5bn
Q2 20252 holders, $17m31 holders, $18.4bn
Q3 20253 holders, $37m32 holders, $23.7bn
Q4 20254 holders, $118m29 holders, $27.8bn
Q1 20262 holders, $84m34 holders, $35.6bn
Q2 20263 holders, $104m33 holders, $39.1bn
ENTA

Enanta Pharmaceuticals Inc

Holders
3
Reported value
$104m
Buyers
7
Sellers
13

Breadth -6 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ENTA (0)

None.

Only JNJ (30)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Soros Fund Management LLC, Squarepoint Ops LLC, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →